Selected synthetic case / actual retained answers
One mechanism can connect a multisystem case
Both answers identify lysinuric protein intolerance. OpenEvidence gives a strong connected physiological explanation; MontMedical separates the findings from post-treatment assay interpretation.
A selected synthetic development case, published by MontMedical. The clinical fingerprints match, but the exact prompts submitted to OpenEvidence were not independently retained. This is an editorial comparison of historical answers, not a blinded efficacy trial.
Our editorial assessment
How the retained answers rate.
OpenEvidence8.2/10
MontMedical7.8/10
OpenEvidence explains the physiology and next steps more effectively.
Same five criteria and weights for both systems| Criterion and weight | OpenEvidence | MontMedical |
|---|
| Diagnosis and case fit 25% | 9/10 | 9/10 |
|---|
| Interpretation of tests and experiments 25% | 8/10 | 8/10 |
|---|
| Strength of the claims 20% | 7/10 | 8/10 |
|---|
| Decisions and next steps 15% | 8/10 | 6/10 |
|---|
| Clarity and teaching 15% | 9/10 | 7/10 |
|---|
Why each criterion received its mark
Diagnosis and case fit
OpenEvidence · 9/10: Correctly unifies the metabolic, pulmonary, renal and inflammatory findings.
MontMedical · 9/10: Correct unifying diagnosis with explicit supporting organ findings.
Interpretation of tests and experiments
OpenEvidence · 8/10: Explains the transport-to-urea-cycle mechanism and acknowledges post-treatment collection.
MontMedical · 8/10: Preserves collection timing and explains why the treated specimen is less informative.
Strength of the claims
OpenEvidence · 7/10: Describes non-diagnostic screens as typical more broadly than the checked case evidence supports.
MontMedical · 8/10: Avoids the blanket frequency claim, though the case-to-mechanism attribution is still compressed.
Decisions and next steps
OpenEvidence · 8/10: Provides confirmatory testing and practical metabolic follow-up.
MontMedical · 6/10: Describes test limitations without an equally explicit confirmatory plan.
Clarity and teaching
OpenEvidence · 9/10: Gives the stronger connected physiological explanation.
MontMedical · 7/10: Useful structure, but repeated findings and a selected severe pulmonary series are less focused teaching.
AI-assisted editorial judgment of these historical texts, published by MontMedical. Read the rubric, anchors and limits. These are answer-quality scores, not measured diagnostic accuracy or patient benefit.
The actual retained wording
OpenEvidence vs MontMedical.
These are verbatim passages from the retained answers, not rewritten examples. Bold, link formatting and line breaks have been removed. Each labelled passage is contiguous; an excerpt may begin within a sentence. Our interpretation and scores are separate.
OpenEvidence
Retained 2026-09-08
Mechanistic explanation
Reduced ornithine and arginine limit urea cycle flux, so protein loading precipitates hyperammonaemic crises exactly as occurred here — agitation, vomiting, hyperventilation with respiratory alkalosis, and obtundation 36 hours after protein intake was advanced, with ammonia rising to 326 µmol/L and improving with protein restriction and ammonia-lowering therapy/haemodiafiltration.
Screen interpretation
Normal fasting ammonia and non-diagnostic amino-acid screens outside of acute catabolic stress are typical, because LPI biochemical markers (low plasma lysine/arginine/ornithine, elevated urinary dibasic amino acids and orotic acid) can be subtle or masked between episodes, and dialysis before the only plasma amino-acid sample further obscures the pattern here.
MontMedical
Retained 2026-09-08
Leading classification
The patient's multisystem presentation—comprising postprandial encephalopathy with severe hyperammonemia following protein loading, secondary hemophagocytic lymphohistiocytosis (HLH), pulmonary alveolar proteinosis, proximal renal tubular dysfunction, and severe osteoporosis—is most consistently explained by lysinuric protein intolerance (LPI).
Screen interpretation
Normal urinary orotic acid and non-specific amino acid findings do not reliably rule out lysinuric protein intolerance, as malnutrition and acute therapeutic interventions can obscure typical diagnostic excretion patterns.
The case and the decision
A synthetic patient develops severe hyperammonaemia after protein feeding, against a background of protein aversion, renal tubular abnormalities, skeletal disease, pulmonary alveolar proteinosis and inflammatory blood findings. Key biochemical specimens were collected after treatment had begun.
Both identify lysinuric protein intolerance as the unifying hypothesis. The pattern spans several organs, so an explanation that accounts only for the acute ammonia result leaves important observations behind.
A genetically confirmed published LPI case had non-diagnostic urinary amino-acid and orotic-acid results. That establishes that such screening results do not invariably exclude the disorder; it does not establish how often that occurs or exactly how treatment changed this synthetic patient's specimen. [1]
How the explanations compare
OpenEvidence connects impaired dibasic amino-acid transport with reduced urea-cycle support and the protein-associated crisis. Its organ-by-organ explanation is educational and coherent. MontMedical uses distinct assessment, findings, limits and research sections, making it easier to inspect where the case observations end and interpretation begins.
Both notice the post-treatment collection issue. There is no defensible diagnostic advantage for MontMedical in this retained pair.
The teaching point
A normal or non-diagnostic result is interpreted in light of what was measured, when it was collected and which mechanism it can test. Neither tool should turn the possibility of a masked profile into a claim that non-diagnostic screens are routinely expected in every patient.
This pair helps define the standard we want: OpenEvidence's connected explanation, combined with explicit specimen timing and a clear account of what would confirm the leading hypothesis.
Retained answer dates: MontMedical 2026-09-08; OpenEvidence 2026-09-08. Excerpt wording was checked against the retained answers; formatting was removed. These versions were selected during development. Complete original run settings and identical submitted prompts are not documented.
This article examines the MontMedical Pro beta using retained diagnostic answers.